Figure 1 | Scientific Reports

Figure 1

From: Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer

Figure 1

SIWA318H binds to CML-BSA in a concentration dependent manner. SIWA318H showed a concentration-dependent binding to CML-BSA that is similar to a commercially available anti-CML antibody (positive control). There was no binding to BSA detected at the highest concentration tested, indicating the high specificity of SIWA318H to the CML glycation epitope.

Back to article page